Marcus, a 28-year-old in a serodiscordant relationship where his partner is HIV-positive and undetectable, sat in my office worried about transmission risk during intimate moments. He’d heard about PrEP but wasn’t sure if it applied to him, whether he could trust it, or how to actually start taking it. Within three months of beginning tenofovir-emtricitabine daily, his anxiety shifted—not disappeared, but shifted into something manageable. He could focus on his relationship instead of catastrophizing about every exposure.
PrEP, or pre-exposure prophylaxis, isn’t about fear. It’s about choice. It’s a medical tool that lets people with higher HIV exposure risk take control of their sexual health without relying entirely on condoms, partner disclosure, or luck. If you’re in a situation like Marcus’s, or if your sexual practices put you at genuine risk, understanding PrEP means understanding one of the most effective HIV prevention tools we have.
Key Facts About PrEP
- When taken daily as prescribed, tenofovir-emtricitabine reduces HIV transmission risk by 99% in people with penis-in-vagina sex and 96% in people with receptive anal intercourse, according to NIH clinical trials
- The FDA approved the on-demand dosing schedule (Truvada taken as two pills 2-24 hours before sex, one pill during, one pill 48 hours after) specifically for men who have sex with men, showing 86% effectiveness in real-world conditions
- Approximately 1.2 million Americans are recommended to be on PrEP based on CDC risk criteria, yet only about 200,000 were actively taking it as of 2022
- Long-acting injectable cabotegravir (Apretude), given as an intramuscular injection every two months, became available in 2023 as an alternative to daily pills with similar efficacy to oral PrEP
- PrEP costs between $1,600-$2,000 monthly without insurance, but most commercial plans and Medicaid cover it completely, plus patient assistance programs exist for uninsured individuals
Understanding How PrEP Actually Works Inside Your Body
Think of PrEP like having security guards stationed at every door to your cells before an intruder shows up. When you take tenofovir-emtricitabine daily, these medications build up in your bloodstream and concentrate in the tissues that HIV targets first—your rectal tissue, vaginal tissue, and blood cells. The medication blocks reverse transcriptase, the enzyme HIV uses to copy its genetic material after entering your cells. Without it, the virus can’t establish infection even if exposure occurs.
The key psychological aspect people miss: PrEP doesn’t make you feel different. You won’t notice it working. That absence of sensation is actually a sign it’s doing its job. Some people experience frustration with this invisibility—they expect to feel “protected,” but protection here is biochemical, not perceptual.
Cabotegravir, the injectable option, works slightly differently by inhibiting integrase, another HIV enzyme responsible for inserting viral DNA into your cell’s genome. Both approaches intercept the virus at different stages before it can replicate.
Who Actually Needs PrEP: Risk Factors That Matter
The CDC provides specific criteria: you should consider PrEP if you’re HIV-negative and have had condomless sex or shared injection equipment in the past six months with someone whose HIV status is unknown or who is HIV-positive. But the numbers tell a different story than the criteria alone.
Serodiscordant couples represent one of the most undertreated groups. When one partner is HIV-positive and undetectable (meaning viral load is below 200 copies per milliliter), the risk of transmission is zero—a concept called Undetectable Equals Untransmittable, or U=U. Yet many such couples never discuss PrEP with their doctors. The shame or fear around the diagnosis keeps them from accessing a straightforward prevention tool.
Men who have sex with men face the highest per-act transmission risk during receptive anal intercourse (roughly 1.38% per act without condom or PrEP according to CDC estimates), making PrEP statistically one of the most important health interventions available to them. Women in relationships with bisexual or unfaithful partners rarely think about PrEP, even though vaginal transmission risk is around 0.08% per act—lower than rectal but still meaningful over time.
Here’s what most articles skip: healthcare workers exposed to needle-stick injuries, incarcerated individuals with high-risk sexual networks, and transgender women—who face both biological vulnerability and structural barriers to healthcare—represent populations with genuine indications that rarely come up in mainstream PrEP discussions. Transgender women specifically have been shown in observational studies to have higher engagement when providers explicitly discuss PrEP as part of their gender-affirming care.
What You Actually Experience: The Daily Reality of PrEP
The first week? Most people experience nothing, or mild nausea that passes. Some report loose stools initially, which typically resolve within two to four weeks. These aren’t dangerous side effects—they’re your GI tract adjusting to the medications.
What you notice over months is the mental shift. People describe less anxiety surrounding sexual moments. They report feeling more agency. Some—not all—report increased sexual confidence because they’ve deprioritized condom dependency, though many continue using condoms for STI prevention since PrEP doesn’t prevent chlamydia, gonorrhea, syphilis, or other infections.
An overlooked early warning sign: if you experience bone pain, severe fatigue, or dark urine after starting PrEP, don’t ignore it. These symptoms are rare but suggest kidney or bone issues that warrant immediate lab work. Most people on PrEP experience no concerning symptoms, but your body’s signals matter.
Adherence is where reality diverges from studies. In controlled trials, nearly perfect adherence yields near-perfect protection. In actual life—where you travel, forget pills, experience life changes—adherence drops. People miss doses. Some intentionally skip doses thinking they’ll have sex later, then the timing doesn’t match research recommendations. This is why we’re seeing the injectable option gain traction; one injection every eight weeks removes the daily decision-making burden.
The Evaluation Process: Testing and Baseline Assessment
Starting PrEP requires more than just asking for the prescription. A responsible provider will order baseline labs: a fourth-generation HIV antibody/antigen test (which detects HIV faster than older tests), hepatitis B serology, renal function tests (creatinine and eGFR), and bone density assessment if you’re over 50 or have risk factors. Why these tests? Because HIV status must be confirmed negative, hepatitis B status affects how your body metabolizes antiretrovirals, kidney function determines safe dosing, and some PrEP medications can affect bone density over years.
The sexual health conversation should feel different from a standard checkup. A skilled provider asks specific, judgment-free questions: How many partners in the past year? What types of sex? What’s your partner’s HIV status? Does anyone use substances that might impair judgment about safer sex? These aren’t invasive questions—they’re diagnostic necessities.
You should leave the visit understanding not just that you need PrEP, but why your specific situation warrants it. If a provider can’t articulate this or makes you feel ashamed about your sexuality, that’s a sign to find someone else.
Treatment Regimens: Which PrEP Option Fits Your Life
Three medications dominate the PrEP landscape currently:
Tenofovir-emtricitabine (Truvada) daily: The original and most studied, taken as one pill once daily. Extensive safety data from thousands of patients over 15+ years. Some people experience mild GI effects initially. Cost is manageable through insurance, though significant without coverage.
Tenofovir alafenamide-emtricitabine (Descovy) daily: A newer formulation with lower kidney and bone toxicity than Truvada, which matters if you have kidney disease or osteoporosis risk. FDA approval came in 2019. It’s not approved for receptive vaginal sex because clinical trials excluded this population, though some providers prescribe off-label. Insurance coverage remains inconsistent compared to Truvada.
Cabotegravir injectable (Apretude) every eight weeks: One intramuscular injection in the deltoid every two months after a one-month loading phase. Eliminates daily pill burden. Some people report injection site reactions—mild soreness, small lumps—that resolve within days. This option excels for people with adherence challenges or those who prefer less frequent dosing. Cost and insurance coverage are still evolving as it’s newer to the market.
On-demand PrEP: Two Truvada pills taken 2-24 hours before anticipated sex, one pill during the sex act (or within 24 hours of first exposure), and one final pill 48 hours later. This approach showed 86% effectiveness in the IPERGAY trial but requires planning. It works best for men with infrequent, predictable sexual occasions. For people with frequent or spontaneous sex, daily dosing provides superior protection.
Managing PrEP Long-Term: Concrete Daily Strategies
Set a specific alarm on your phone—not a vague reminder, but tied to an existing daily habit. Some patients pair their morning pill with coffee. Others take it with lunch. The most successful PrEP adherence happens when the medication integrates into an existing routine, not a new one you have to remember.
Use a pill organizer with dates visible. This transforms PrEP from an abstract health responsibility into something visual you check off daily. You can quickly see if you’ve already taken it—eliminating the “did I take this or not?” anxiety that leads to missed doses or accidental double-dosing.
Schedule your lab work in advance. You need HIV testing every three months while on PrEP, renal function testing at baseline and annually, and hepatitis B serology at baseline. Mark these appointments on your calendar now. If you skip labs, you lose clinical oversight of potential complications, and your provider can’t responsibly continue the prescription.
Communicate STI exposure honestly with your provider. PrEP is phenomenally effective at preventing HIV, but chlamydia, gonorrhea, and syphilis still transmit easily. Some research suggests frequent STI testing and treatment while on PrEP might increase antibiotic resistance—so discussing sexual practices with your doctor isn’t judgment; it’s collaborative risk management.
Join a community. Online forums, local PrEP advocacy groups, and LGBTQ+ health centers connect you with others navigating the same medication. You’ll hear about real side effects, insurance hassles, and the genuine psychological benefits others experience. Isolation fuels medication non-adherence; community reinforces it.
Prevention: What the Evidence Actually Shows Works
PrEP prevents HIV transmission. That’s the central fact. But prevention isn’t purely chemical. A NEJM study from 2017 found that people who start PrEP often reduce other risk-taking behavior simultaneously—they become more conscious of sexual health broadly. Some increase condom use. Others reduce the number of partners. This behavioral shift compounds the chemical protection.
However—and this is crucial—PrEP doesn’t prevent other sexually transmitted infections. You still need condoms for gonorrhea, chlamydia, syphilis, herpes, and HPV transmission. Some patients interpret PrEP as a license to abandon condoms entirely, then find themselves treating recurrent STIs. Prevention means using multiple tools: PrEP for HIV, condoms for other infections, regular testing, and partner communication.
For serodiscordant couples specifically, the most robust prevention combines PrEP for the negative partner and confirmed undetectable viral load for the positive partner (U=U principle). This dual approach reduces transmission risk to effectively zero even without condoms, though most couples still use them for psychological comfort.
